<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159908</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-921352-FOS2021</org_study_id>
    <secondary_id>2021-001433-39</secondary_id>
    <nct_id>NCT05159908</nct_id>
  </id_info>
  <brief_title>A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects With Focal Onset Seizures (FOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses&#xD;
      of NBI-921352 versus placebo in adults with focal onset seizures&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation of Study Treatment, and Fatal TEAEs</measure>
    <time_frame>Through Week 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average plasma concentration of NBI-921352</measure>
    <time_frame>Predose and up to 8 hours postdose throughout the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Monthly Focal Onset Seizure Frequency During the Treatment Period</measure>
    <time_frame>Baseline and Weeks 1 to 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Monthly Focal Onset Seizure Frequency During the Maintenance period</measure>
    <time_frame>Baseline and Weeks 4 to 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC) Scores at Week 11</measure>
    <time_frame>Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a ≥ 50% reduction in monthly (28 days) focal onset seizure frequency during the treatment period</measure>
    <time_frame>Baseline and Weeks 1 to 11</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Focal Onset Seizure</condition>
  <condition>Focal Onset Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo schedule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant follows Placebo schedule (13 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant follows Dose schedule A (13 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant follows Dose schedule B (13 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose schedule C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant follows Dose schedule C (13 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-921352</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Dose schedule A</arm_group_label>
    <arm_group_label>Dose schedule B</arm_group_label>
    <arm_group_label>Dose schedule C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets for oral administration</description>
    <arm_group_label>Placebo schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Capable of providing consent and has completed the written informed consent.&#xD;
&#xD;
          2. Male or female, 18 to 65 years of age, inclusive, with a body mass index (BMI) &lt; 40&#xD;
             kg/m^2.&#xD;
&#xD;
          3. Diagnosis of focal onset epilepsy according to the International League Against&#xD;
             Epilepsy (ILAE) Classification of Epilepsy (2017) at least 18 months before screening.&#xD;
&#xD;
          4. History of uncontrolled seizures despite adequate treatment with at least 1&#xD;
             anti-seizure medication (ASM) for at least 18 months prior to screening.&#xD;
&#xD;
          5. Treatment with at least 1 but not more than 4 ASMs for at least 1 month before&#xD;
             screening, during the baseline seizure diary data collection, and throughout the&#xD;
             duration of the study.&#xD;
&#xD;
          6. Be able to keep accurate seizure diaries.&#xD;
&#xD;
          7. Documented seizure frequency in the baseline seizure diary of ≥8 countable focal&#xD;
             seizures during the 8-week seizure baseline period.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of epilepsy with only nonmotor seizures without an observable component,&#xD;
             psychogenic nonepileptic seizures, or primary generalized seizures.&#xD;
&#xD;
          2. Presence or previous history of developmental and/or epileptic encephalopathy.&#xD;
&#xD;
          3. Presence of seizure types other than FOS.&#xD;
&#xD;
          4. History of repetitive seizures within the 12-month period preceding study entry where&#xD;
             the individual seizures cannot be counted.&#xD;
&#xD;
          5. Status epilepticus within the last 12 months before enrollment.&#xD;
&#xD;
          6. Any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with&#xD;
             some intent to act, without specific plan) or type 5 (active suicidal ideation with&#xD;
             specific plan and intent) based on the C-SSRS in the 2 years before screening, a&#xD;
             history of suicide attempt in the last 2 years, or more than 1 lifetime suicide&#xD;
             attempt.&#xD;
&#xD;
          7. History or presence of any significant medical or surgical condition, lab value, or&#xD;
             concomitant medication that would place the subject at increased risk.&#xD;
&#xD;
          8. A known history of clinically concerning cardiac arrhythmia (including long QT&#xD;
             syndrome) or prolongation of screening (pre-treatment) QT interval corrected for heart&#xD;
             rate.&#xD;
&#xD;
          9. Require use of rescue medication more than once per week.&#xD;
&#xD;
         10. Multiple drug allergies or a severe drug reaction to an ASM(s), including&#xD;
             dermatological (eg, Stevens-Johnson syndrome), hematological, or organ toxicity&#xD;
             reactions.&#xD;
&#xD;
         11. An implanted responsive neurostimulator system (RNS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neurocrine Medical Information Call Center</last_name>
    <phone>877-641-3461</phone>
    <email>medinfo@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Praha 8</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Rychnov Nad Kněžnou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>December 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>focal seizure</keyword>
  <keyword>sodium channel</keyword>
  <keyword>voltage-gated</keyword>
  <keyword>alpha subunit</keyword>
  <keyword>Nav1.6 inhibitor</keyword>
  <keyword>Antiseizure medication</keyword>
  <keyword>ASM</keyword>
  <keyword>Antiepileptic drug</keyword>
  <keyword>AED</keyword>
  <keyword>partial seizure</keyword>
  <keyword>partial onset epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

